Loading…
The acquisition is valued at $48 million.
KALA Bio, Inc. (Nasdaq: KALA) announced it has signed a non-binding Letter of Intent (LOI) to acquire a nationwide telehealth platform. The acquisition is valued at $48 million.
The telehealth platform will expand KALA Bio's service offerings and market reach. The company aims to leverage the platform to enhance its biotechnology services.
KALA Bio has a free float of 18,588,345 shares and 19,339,786 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.